Literature DB >> 11444389

Immunotherapy of inflammatory demyelinating diseases of the central nervous system.

J J Bright1, S Sriram.   

Abstract

Inflammatory demyelinating diseases comprise a heterogeneous group of disorders that affect the peripheral and central nervous system. Multiple sclerosis (MS) is the most common disease affecting the CNS white matter. Close similarities between MS and the animal model of the disease, experimental allergic encephalitis (EAE), have suggested that MS might be an autoimmune disease, which is triggered by an infectious agent. Our laboratory has directed its effort in identifying and designing therapies that interfere with key signaling pathways that mediate CNS inflammation in experimental allergic encephalitis. These have included naturally occurring cytokines such as TGFbeta and synthetic small molecules, lysofyline and tyrphostin, which inhibit the inflammatory response and prevent the development of EAE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444389     DOI: 10.1385/IR:23:2-3:245

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  41 in total

1.  The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis.

Authors:  D A Hafler
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 2.  Resolving conflicting signals: cross inhibition of cytokine signaling pathways.

Authors:  C G Begley; N A Nicola
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

Review 3.  Animal models of myasthenia gravis.

Authors:  P Christadoss; M Poussin; C Deng
Journal:  Clin Immunol       Date:  2000-02       Impact factor: 3.969

Review 4.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

Authors:  G Trinchieri
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

Review 5.  Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling.

Authors:  T Hunter
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

6.  Tyrphostin AG 494 blocks Cdk2 activation.

Authors:  N Osherov; A Levitzki
Journal:  FEBS Lett       Date:  1997-06-30       Impact factor: 4.124

7.  Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1.

Authors:  L D Johns; K C Flanders; G E Ranges; S Sriram
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

8.  Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis.

Authors:  F Nicoletti; F Patti; C Cocuzza; P Zaccone; A Nicoletti; R Di Marco; A Reggio
Journal:  J Neuroimmunol       Date:  1996-10       Impact factor: 3.478

Review 9.  The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis.

Authors:  T Owens; S Sriram
Journal:  Neurol Clin       Date:  1995-02       Impact factor: 3.806

10.  Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice.

Authors:  E Abraham; S Bursten; R Shenkar; J Allbee; R Tuder; P Woodson; D M Guidot; G Rice; J W Singer; J E Repine
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  Xu Zhang; Raymond Hupperts; Marc De Baets
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 2.  Cannabinoids and neuroinflammation.

Authors:  Lisa Walter; Nephi Stella
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

3.  15-deoxy-Delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte.

Authors:  Wanida Chearwae; John J Bright
Journal:  J Clin Immunol       Date:  2008-05-08       Impact factor: 8.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.